Phadke Pushkar A, Mercer Robyn R, Harms John F, Jia Yujiang, Frost Andra R, Jewell Jennifer L, Bussard Karen M, Nelson Shakira, Moore Cynthia, Kappes John C, Gay Carol V, Mastro Andrea M, Welch Danny R
Department of Pathology, Comprehensive Cancer Center, Center for Metabolic Bone Disease, National Foundation for Cancer Research, Center for Metastasis Research, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.
Clin Cancer Res. 2006 Mar 1;12(5):1431-40. doi: 10.1158/1078-0432.CCR-05-1806.
In vivo studies have focused on the latter stages of the bone metastatic process (osteolysis), whereas little is known about earlier events, e.g., arrival, localization, and initial colonization. Defining these initial steps may potentially identify the critical points susceptible to therapeutic intervention.
MDA-MB-435 human breast cancer cells engineered with green fluorescent protein were injected into the cardiac left ventricle of athymic mice. Femurs were analyzed by fluorescence microscopy, immunohistochemistry, real-time PCR, flow cytometry, and histomorphometry at times ranging from 1 hour to 6 weeks.
Single cells were found in distal metaphyses at 1 hour postinjection and remained as single cells up to 72 hours. Diaphyseal arrest occurred rarely and few cells remained there after 24 hours. At 1 week, numerous foci (2-10 cells) were observed, mostly adjacent to osteoblast-like cells. By 2 weeks, fewer but larger foci (> or =50 cells) were seen. Most bones had a single large mass at 4 weeks (originating from a colony or coalescing foci) which extended into the diaphysis by 4 to 6 weeks. Little change (<20%) in osteoblast or osteoclast numbers was observed at 2 weeks, but at 4 to 6 weeks, osteoblasts were dramatically reduced (8% of control), whereas osteoclasts were reduced modestly (to approximately 60% of control).
Early arrest in metaphysis and minimal retention in diaphysis highlight the importance of the local milieu in determining metastatic potential. These results extend the Seed and Soil hypothesis by demonstrating both intertissue and intratissue differences governing metastatic location. Ours is the first in vivo evidence that tumor cells influence not only osteoclasts, as widely believed, but also eliminate functional osteoblasts, thereby restructuring the bone microenvironment to favor osteolysis. The data may also explain why patients receiving bisphosphonates fail to heal bone despite inhibiting resorption, implying that concurrent strategies that restore osteoblast function are needed to effectively treat osteolytic bone metastases.
体内研究主要聚焦于骨转移过程的后期阶段(骨溶解),而对于早期事件,如癌细胞的到达、定位和初始定植,我们却知之甚少。明确这些初始步骤可能有助于确定易于进行治疗干预的关键点。
将经过绿色荧光蛋白工程改造的MDA-MB-435人乳腺癌细胞注射到无胸腺小鼠的左心室。在注射后1小时至6周的不同时间点,通过荧光显微镜、免疫组织化学、实时PCR、流式细胞术和组织形态计量学对股骨进行分析。
注射后1小时,在远端干骺端发现单个细胞,直至72小时这些细胞仍为单个细胞。骨干停滞很少发生,24小时后很少有细胞留在那里。在1周时,观察到大量病灶(2 - 10个细胞),大多邻近成骨细胞样细胞。到2周时,病灶数量减少但更大(≥50个细胞)。大多数骨骼在4周时出现单个大肿块(源自一个集落或融合的病灶),到4至6周时扩展至骨干。在2周时,成骨细胞或破骨细胞数量变化不大(<20%),但在4至6周时,成骨细胞显著减少(降至对照的8%),而破骨细胞适度减少(降至对照的约60%)。
在干骺端的早期停滞以及在骨干的极少滞留突出了局部微环境在决定转移潜能方面的重要性。这些结果扩展了“种子与土壤”假说,证明了组织间和组织内差异对转移定位的影响。我们首次提供了体内证据,表明肿瘤细胞不仅如普遍认为的那样影响破骨细胞,还会消除功能性成骨细胞,从而重塑骨微环境以利于骨溶解。这些数据也可以解释为什么接受双膦酸盐治疗的患者尽管抑制了骨吸收但骨仍无法愈合,这意味着需要同时采取恢复成骨细胞功能的策略来有效治疗溶骨性骨转移。